Literature DB >> 23774609

Postprandial lipoproteins and the molecular regulation of vascular homeostasis.

Kathleen M Botham1, Caroline P D Wheeler-Jones.   

Abstract

Blood levels of triglyceride-rich lipoproteins (TRL) increase postprandially, and a delay in their clearance results in postprandial hyperlipidemia, an important risk factor in atherosclerosis development. Atherosclerosis is a multifactorial inflammatory disease, and its initiation involves endothelial dysfunction, invasion of the artery wall by leukocytes and subsequent formation of foam cells. TRL are implicated in several of these inflammatory processes, including the formation of damaging free radicals, leukocyte activation, endothelial dysfunction and foam cell formation. Recent studies have provided insights into the mechanisms of uptake and the signal transduction pathways mediating the interactions of TRL with leukocytes and vascular cells, and how they are modified by dietary lipids. Multiple receptor and non-receptor mediated pathways function in macrophage uptake of TRL. TRL also induce expression of adhesion molecules, cyclooxygenase-2 and heme-oxygenase-1 in endothelial cells, and activate intracellular signaling pathways involving mitogen-activated protein kinases, NF-κB and Nrf2. Many of these effects are strongly influenced by dietary components carried in TRL. There is extensive evidence indicating that raised postprandial TRL levels are a risk factor for atherosclerosis, but the molecular mechanisms involved are only now becoming appreciated. Here, we review current understanding of the mechanisms by which TRL influence vascular cell function.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine; ABC; AMP kinase; AMPK; AP; ATP binding cassette transporter; Akt; Apo; C reactive protein; CD; CM; CMR; COX; CREB; CRP; DHA; EC; EGF; EPA; EPC; ERK; Egr; Endothelial cells; FAK; FFA; GPIHBP1; HAEC; HDL; HMDM; HO; HSPG; HUVEC; ICAM; IFN; IL; Inflammation; IκB; JNK; LDL; LDLR; LOX; LPL; LPS; LR11; LRP; M1; M2; MAPK; MCP; MEK; MIP; MMP; MUFA; Macrophages; Monocytes; Mox; NAD(P)H oxidase; NF-κB; NO; Nox; Nrf; P; PAI-1; PAPC; PGE(2); PKC; PL; POA; PPAR; PUFA; Postprandial lipemia; RAP; RLP; ROS; RXR; SFA; SR; TG; TGF; TLR; TNF; TRL; Triglyceride-rich lipoproteins; V; VCAM; VE cadherin; VEGF; VLDL; VLDLR; VSMC; activator protein; alternatively activated macrophages; apoB48R; apolipoprotein; apolipoprotein B48 receptor; c-Jun N-terminal kinase; cAMP response element binding; chylomicron remnants; chylomicrons; classically activated macrophages; cluster of differentiation; cyclooxygenase; docosahexaenoic acid; eNOS; early growth response protein; eicosapentaenoic acid; endothelial cell; endothelial nitric oxide synthase; endothelial progenitor cell; epidermal growth factor; extracellular-signal-regulated kinase; focal adhesion kinase; free fatty acid; glycosylphosphatidylinositol-anchored high density lipoprotein binding protein 1; hemeoxygenase; heparan sulfate proteoglycans; high density lipoprotein; human aortic endothelial cell; human monocyte-derived macrophages; human umbilical vein endothelial cells; inhibitor of κB; intercellular adhesion molecule; interferon; interleukin; lectin-like oxidized low density lipoprotein receptor; lipopolysaccharide; lipoprotein lipase; low density lipoprotein; low density lipoprotein receptor; low density lipoprotein receptor-related protein; macrophage inflammatory protein; macrophage phenotype induced by oxidised phospholipids; matrix-metalloproteinase; mitogen activated protein kinase kinase; mitogen-activated kinase; monocyte chemoattractant protein; monousaturated fatty acids; nitric oxide; nuclear factor (erythroid-derived 2)-like 2; nuclear factor-κB; ox; oxidized; peroxisome proliferator-activated receptor; phospholipid; plasminogen activator inhibitor type 1; polyunsaturated fatty acids; pomace oil supplemented with oleanolic acid test meal; pomace olive oil test meal; prostglandin E2; protein kinase B; protein kinase C; reactive oxygen species; receptor associated protein; remnant-like particles; retinoid X receptor; saturated fatty acids; scavenger receptor; sortilin-related receptor; toll-like receptor; transforming growth factor; triacylglycerol; triglyceride-rich lipoproteins; tumor necrosis factor; vascular cell adhesion molecule; vascular endothelial cadherin; vascular endothelial growth factor; vascular smooth muscle cells; very low density lipoprotein; very low density lipoprotein receptor; virgin olive oil test meal

Mesh:

Substances:

Year:  2013        PMID: 23774609     DOI: 10.1016/j.plipres.2013.06.001

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  35 in total

1.  Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation.

Authors:  Rebecca A Chmielowski; Dalia S Abdelhamid; Jonathan J Faig; Latrisha K Petersen; Carol R Gardner; Kathryn E Uhrich; Laurie B Joseph; Prabhas V Moghe
Journal:  Acta Biomater       Date:  2017-05-15       Impact factor: 8.947

2.  Dairy cheese consumption ameliorates single-meal sodium-induced cutaneous microvascular dysfunction by reducing ascorbate-sensitive oxidants in healthy older adults.

Authors:  Anna E Stanhewicz; Billie K Alba; W Larry Kenney; Lacy M Alexander
Journal:  Br J Nutr       Date:  2016-07-01       Impact factor: 3.718

3.  Postprandial lipids accelerate and redirect nitric oxide consumption in plasma.

Authors:  Kurt Vrancken; Hobe J Schroeder; Lawrence D Longo; Gordon G Power; Arlin B Blood
Journal:  Nitric Oxide       Date:  2016-03-25       Impact factor: 4.427

4.  Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN.

Authors:  Jing-Yun Zhang; Jun Ma; Pei Yu; Guang-Jie Tang; Chun-Jun Li; De-Min Yu; Qiu-Mei Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

5.  MiR-29b mimics promotes cell apoptosis of smooth muscle cells via targeting on MMP-2.

Authors:  Lingguang Shen; Yanhui Song; Yuqin Fu; Peipei Li
Journal:  Cytotechnology       Date:  2017-10-07       Impact factor: 2.058

6.  Effect of high-carbohydrate or high-monounsaturated fatty acid diets on blood pressure: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Elena Jovanovski; Any de Castro Ruiz Marques; Dandan Li; Hoang V T Ho; Sonia Blanco Mejia; John L Sievenpiper; Andreea Zurbau; Allison Komishon; Lea Duvnjak; Roberto B Bazotte; Vladimir Vuksan
Journal:  Nutr Rev       Date:  2019-01-01       Impact factor: 7.110

Review 7.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

8.  Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Authors:  Maritza J Romero; Rudolf Lucas; Huijuan Dou; Supriya Sridhar; Istvan Czikora; Eby M Mosieri; Ferenc G Rick; Norman L Block; Subbaramiah Sridhar; David Fulton; Neal L Weintraub; Zsolt Bagi; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

9.  Adaptation of β-Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin Resistance.

Authors:  Barry E Hurwitz; Neil Schneiderman; Jennifer B Marks; Armando J Mendez; Alex Gonzalez; Maria M Llabre; Steven R Smith; Roberto Bizzotto; Eleonora Santini; Maria Laura Manca; Jay S Skyler; Andrea Mari; Ele Ferrannini
Journal:  Diabetes       Date:  2015-03-09       Impact factor: 9.461

10.  Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial.

Authors:  Rodney A Velliquette; Kerry Grann; Stephen R Missler; Jennifer Patterson; Chun Hu; Kevin W Gellenbeck; Jeffrey D Scholten; R Keith Randolph
Journal:  Nutr Metab (Lond)       Date:  2015-08-06       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.